Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study
Article first published online: 12 MAY 2003
Acta Psychiatrica Scandinavica
Volume 107, Issue 5, pages 344–350, May 2003
How to Cite
Søholm, B. and Lublin, H. (2003), Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study. Acta Psychiatrica Scandinavica, 107: 344–350. doi: 10.1034/j.1600-0447.2003.00063.x
- Issue published online: 12 MAY 2003
- Article first published online: 12 MAY 2003
- Accepted for publication November 11, 2002
- weight gain;
Objective: To evaluate the long-term effectiveness of the second generation antipsychotics, risperidone and olanzapine on hospitalization, clinical response, and adherence to therapy after switching from conventional antipsychotics or clozapine in a naturalistic setting of schizophrenic patients.
Method: Data were registered for periods of identical duration before and after switching.
Results: Fifty-seven patients were included. Mean study period was 3.1 ± 0.2 years. Mean number of in-patient days after switching declined by 78% of the level before switching (P=0.0002). There was no significant differences in ratio responders/non-responders between the subgroups. The number of patients with extrapyramidal symptoms (EPS) was significantly reduced after switching. However, intolerable weight gain led to a lack of adherence to therapy in 18% of the olanzapine-treated patients.
Conclusion: Long-term treatment with the second generation antipsychotics, risperidone and olanzapine significantly improved the clinical outcome. However, weight gain may be a significant reason for discontinuation of treatment and reducing the long-term adherence to therapy.